Glucomannan is a water-soluble, highly viscous dietary fiber composed primarily of glucose and mannose units, naturally occurring in the konjac plant (Amorphophallus konjac) and studied in humans for cholesterol regulation, weight management, gastrointestinal function, and glycemic control. (NIH ODS)
Glucomannan is a plant-derived polysaccharide that absorbs water and forms a thick gel within the digestive tract. Its most consistently studied effects involve reductions in total and LDL cholesterol, while randomized trials have produced less consistent results for weight loss, constipation, and glucose regulation. (Review) (Review) Clinical studies have evaluated glucomannan as capsules, powders, fiber-enriched foods, and combination formulations, making delivery method an important consideration when comparing findings. (Research) The overall human evidence is moderate for improvements in blood lipid markers but limited or mixed for broader clinical outcomes. (Review)
Ingredient Identity
Official name: Glucomannan.
Synonyms: Konjac glucomannan (KGM), konjac mannan, konjac gum, and konjac-derived soluble dietary fiber.
Classification: Water-soluble, highly viscous, largely nondigestible dietary polysaccharide.
Botanical source: Amorphophallus konjac, particularly the plant’s underground storage organ.
CAS number: 11078-31-2 (commonly associated with glucomannan).
Endogenous vs. exogenous: Exogenous dietary carbohydrate polymer; not synthesized by the human body as a native nutrient.
The chemical and botanical classification is consistent with the ingredient descriptions used in NIH ODS and EFSA assessments. (NIH ODS) (EFSA)
Ingredient Snapshot
Classification: Plant-derived, water-soluble, highly viscous dietary fiber composed mainly of mannose and glucose units. (NIH ODS)
Endogenous vs. Exogenous Status: Obtained externally from konjac-derived foods and manufactured fiber ingredients; it is not a substance naturally synthesized by human tissues. (EFSA)
Primary Human Research Domains: Cardiovascular Health, Obesity and Weight Regulation, Digestive and Gastrointestinal Health, Diabetes and Glycemic Control, and Nutrition and Deficiencies. (Review)
Common Study Formats: Randomized placebo-controlled trials, crossover feeding studies, glucomannan-enriched foods, and systematic reviews of oral fiber supplementation. (Research) (Research)
Pharmacokinetic Characterization Status: Research focuses mainly on gastrointestinal hydration, viscosity, intestinal transit, and physiological responses rather than systemic blood concentrations of intact glucomannan. (NIH ODS)
Regulatory Context (U.S./EU): Glucomannan is used in dietary supplement and food contexts; EU regulations authorize specified health claims under defined conditions, while U.S. authorities identify important gastrointestinal and swallowing-related safety considerations. (NIH ODS) (EU Regulation)
Evidence Maturity: Moderate for total and LDL cholesterol biomarkers; limited or mixed for weight loss, bowel-function outcomes, and glycemic control. (Review) (Review)
Introduction
Glucomannan is a naturally occurring dietary fiber extracted primarily from the konjac plant. Unlike digestible carbohydrates that are broken down into sugars and absorbed, glucomannan largely remains within the gastrointestinal tract, where its ability to bind water and develop viscosity influences its physical behavior. Konjac-derived ingredients appear in food products as well as concentrated fiber preparations. (NIH ODS) (EFSA)
Interest in glucomannan research comes from the relationship between soluble-fiber viscosity and digestive physiology. Human investigations have evaluated its effects on blood cholesterol, glucose metabolism, bowel movements, fullness, and body weight. These outcomes do not respond uniformly: reductions in LDL cholesterol have appeared in multiple trials and meta-analyses, whereas weight-loss and constipation outcomes are less consistent. (Review) (Review)
This article is informational only, describes glucomannan as a dietary polysaccharide studied in human research, and does not provide medical or dosing advice.
Quick Summary
- Glucomannan is a soluble dietary fiber derived from konjac, characterized by its ability to absorb water and form a viscous gel in the digestive tract. (NIH ODS)
- Cardiovascular Health has the most consistent human evidence, with randomized trials and meta-analyses reporting reductions in LDL and total cholesterol. (Review)
- Obesity and Weight Regulation findings are mixed to largely neutral, with a meta-analysis finding no statistically significant overall weight-loss effect compared with placebo. (Review)
- Digestive and Gastrointestinal Health studies have reported changes in bowel-movement frequency, but overall constipation-treatment success has not consistently improved. (Review)
- Diabetes and Glycemic Control research includes short-term improvements in selected glucose-related markers, although intervention studies vary in population, formulation, and findings. (Research) (Review)
- Glucomannan has been studied in capsules and fiber-enriched foods, where hydration, food structure, and viscosity can alter its physiological behavior. (Research)
- A documented safety concern is the potential for swelling fiber to cause swallowing or esophageal obstruction, particularly when inadequately hydrated. (FDA)
Human Research Findings by Condition
Cardiovascular Health
Human cardiovascular research on glucomannan focuses primarily on cholesterol and other circulating lipid markers rather than cardiovascular events. Randomized trials and meta-analyses have reported relatively consistent reductions in total and LDL cholesterol, although effects on other lipid measures and the longer-term clinical significance remain less certain. (Review) (Review)
Key human study — Arvill and Bodin, 1995
Dose studied: 3.9 g/day
Population: 63 healthy men
Duration: Two four-week intervention periods in a crossover design
Researchers compared glucomannan with placebo and examined circulating blood lipids. Total cholesterol fell by approximately 10%, LDL cholesterol by 7.2%, and triglycerides by 23% relative to placebo during the reported study conditions.
These outcomes measured intermediate cardiovascular risk markers rather than heart attacks, strokes, or mortality.
Result: Randomized human trial reported a statistically significant improvement in lipid markers.
Evidence strength: Moderate
Study source: (Research)
Additional human study — Vuksan et al., 2003
Dose studied: Glucomannan supplementation; the precise exposure is not established from the collected source summary
Population: 22 adults with type 2 diabetes and elevated blood cholesterol
Duration: Two 28-day intervention periods
This controlled crossover investigation evaluated both lipid and glycemic responses. The researchers reported reductions in total and LDL cholesterol, including an approximately 20.7% relative reduction in LDL cholesterol under the comparison conditions.
The study also examined fecal sterol and bile acid excretion, providing physiological context for the lipid findings.
Result: Randomized human trial reported a statistically significant improvement.
Evidence strength: Limited
Study source: (Research)
Additional research context
A 2017 meta-analysis pooling 12 randomized trials and 370 participants found reductions in LDL and non-HDL cholesterol, but did not identify a clear effect on apolipoprotein B. This distinction matters because improvements in conventional cholesterol measurements do not mean that every lipid-related cardiovascular marker responds equally. (Review)
Obesity and Weight Regulation
Glucomannan has been studied for body weight because its ability to thicken gastrointestinal contents may influence fullness and food intake. However, randomized trials and meta-analyses have not consistently established meaningful additional weight loss relative to placebo or background dietary interventions. (Review) (NIH ODS)
Key human study — Keithley et al., 2013
Dose studied: 1.33 g three times daily, totaling 3.99 g/day
Population: 53 adults with overweight or moderate obesity
Duration: 8 weeks
Investigators measured changes in body weight, body composition, and subjective appetite-related outcomes during placebo-controlled supplementation. Glucomannan did not produce a statistically significant improvement in weight loss compared with placebo.
The findings also did not establish consistent improvements in body composition or measured hunger and fullness.
Result: Human clinical study reported no clear effect.
Evidence strength: Moderate
Study source: (Research)
Additional human study — Zalewski et al., 2019
Dose studied: 3 g/day
Population: 96 children and adolescents with overweight or obesity
Duration: 12 weeks, with additional follow-up
This randomized investigation assessed changes in BMI-for-age and related metabolic measurements. Glucomannan did not significantly improve the primary weight-related outcome compared with placebo, although selected cholesterol measurements changed.
The findings provide an additional example of lipid and weight outcomes responding differently within the same intervention.
Result: Human clinical study reported no clear effect on weight-related outcomes.
Evidence strength: Moderate
Study source: (Research)
Additional research context
A systematic review and meta-analysis of eight randomized studies did not find a statistically significant overall weight-loss effect. This pooled result limits confidence in isolated positive findings from individual short-term trials. (Review)
Digestive and Gastrointestinal Health
Human research has investigated glucomannan for constipation because it can absorb water and change the physical properties of intestinal contents. Studies have reported mixed results, with some improvements in bowel-movement frequency but inconsistent changes in overall constipation-treatment success, stool symptoms, and abdominal discomfort. (Review)
Key human study — Chmielewska et al., 2011
Dose studied: 2.52 g/day
Population: 80 children aged 3–16 years with functional constipation
Duration: 4 weeks
Researchers compared glucomannan with placebo using predefined constipation outcomes. The trial did not demonstrate a significant difference in overall treatment success.
Abdominal-pain episodes were also reported more frequently in the glucomannan group during certain weeks, emphasizing that changes in fiber intake can influence gastrointestinal tolerability.
Result: Human clinical study reported no clear effect.
Evidence strength: Moderate
Study source: (Research)
Additional human study — Loening-Baucke et al., 2004
Dose studied: Weight-based glucomannan exposure; the exact numerical regimen is not confirmed from the collected study summary
Population: Children with chronic constipation
Duration: Approximately 4 weeks
This controlled pediatric investigation reported favorable findings for selected constipation-related outcomes. However, its results differed from those of later trials that used other participant groups and definitions of successful treatment.
Result: Human clinical study reported a modest improvement.
Evidence strength: Limited
Study source: (Research)
Additional research context
A systematic review of three pediatric trials involving 122 participants reported improved bowel-movement frequency but no statistically significant improvement in overall treatment success. This demonstrates why stool frequency and broader constipation outcomes should be evaluated separately. (Review)
Diabetes and Glycemic Control
Glucomannan research in Diabetes and Glycemic Control has examined fasting glucose, fructosamine, insulin sensitivity, and post-meal metabolic responses. Small controlled studies have reported favorable changes in certain markers, while meta-analytic findings remain sensitive to the included studies and analytical approach. (Review) (Review)
Key human study — Vuksan et al., 1999
Dose studied: Test biscuits containing 0.7 g glucomannan per 100 kcal
Population: 11 adults with type 2 diabetes
Duration: Two three-week treatment periods
Researchers incorporated glucomannan into biscuits and assessed metabolic effects relative to a comparison food. Selected changes were observed in fructosamine, a blood marker reflecting shorter-term glucose exposure, and cardiovascular risk-related measures.
The findings concern a specific fortified-food intervention rather than glucomannan administered independently as a capsule.
Result: Human clinical study reported a modest improvement.
Evidence strength: Limited
Study source: (Research)
Additional human study — Vuksan et al., 2003
Dose studied: Glucomannan supplementation; exact numerical dose not confirmed in the collected summary
Population: 22 adults with type 2 diabetes and elevated cholesterol
Duration: Two 28-day intervention periods
The study examined lipid metabolism and glucose-related outcomes. Researchers reported lower fasting glucose alongside changes in cholesterol and fecal sterol excretion.
Because of the small population and short intervention periods, the study is more informative about intermediate metabolic outcomes than long-term diabetes complications.
Result: Randomized human trial reported a statistically significant improvement.
Evidence strength: Limited
Study source: (Research)
Additional research context
A 2023 meta-analysis reported favorable pooled results for selected glucose and lipid outcomes, while a newer synthesis found that some fasting-glucose findings depended on statistical assumptions. Taken together, the evidence remains heterogeneous rather than conclusive for sustained glycemic outcomes. (Review) (Review)
Nutrition and Deficiencies
Glucomannan is studied in nutrition research as a functional dietary fiber rather than as an essential nutrient with a defined glucomannan-specific deficiency syndrome. Human feeding studies have examined how fiber viscosity, food structure, and energy density influence fullness and subsequent food consumption. (Research) (NIH ODS)
Key human study — Viscosity and appetite trial, 2020
Dose studied: Glucomannan-containing test meals with differing viscosity; exact glucomannan exposure not established from the collected summary
Population: 22 healthy adults
Duration: Four acute test-meal sessions
Researchers compared the effects of meals designed to differ in viscosity. Higher viscosity increased reported fullness, but the associated reduction in subsequent energy intake was small.
The study suggests that perceived fullness and actual eating behavior may respond differently to the physical characteristics of fiber-containing foods.
Result: Human studies observed short-term physiological effects.
Evidence strength: Limited
Study source: (Research)
Additional human study — Gelled glucomannan food trial, 2017
Dose studied: Glucomannan-containing gel noodles; exact exposure not established from the collected summary
Population: Healthy study participants
Duration: Acute crossover feeding investigation
This experiment examined the effects of gelled food formulations and energy density on appetite-related measurements. Results did not establish a simple relationship between including glucomannan-containing noodles and improved subjective appetite.
Because the investigation manipulated food properties, the outcome cannot be interpreted as the effect of isolated glucomannan alone.
Result: Human clinical study reported no clear effect.
Evidence strength: Limited
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Glucomannan studies have investigated exposures measured in grams per day, weight-based quantities, and fiber concentrations within prepared foods. Unlike small molecules studied through circulating drug concentrations, glucomannan research generally characterizes exposure through the amount administered and its gastrointestinal effects. Differences in food structure, viscosity, hydration, and concurrent ingredients complicate direct comparison between studies. (Research) (Research)
The exposure bands below are presented in ascending order for confirmed fixed daily quantities, preceded by food-based exposures whose daily totals were not established. These are descriptions of research protocols, not intake recommendations.
Food-based exposures
0.7 g per 100 kcal of test food:
An early crossover investigation incorporated glucomannan into biscuits provided to 11 adults with type 2 diabetes. The study expressed the fiber quantity relative to food energy rather than as a uniform fixed daily dose. Participants consumed experimental and control foods during separate three-week phases. Researchers measured fructosamine and selected metabolic risk markers and reported favorable changes during the glucomannan intervention. The design is useful for understanding glucomannan incorporated into food, but the exposure cannot be directly ranked against fixed grams-per-day interventions without knowing total food consumption. (Research)
Result: Modest improvement
Evidence strength: Limited
Notes / limitations: Food concentration is not equivalent to a fixed daily glucomannan dose.
Fixed supplemental exposures
1.5 g/day glucomannan combined with 1.5 g/day inulin:
A randomized investigation evaluated glucomannan and inulin incorporated into yogurt in 80 adults with type 2 diabetes. The intervention lasted eight weeks and examined selected measures of glucose metabolism and blood lipids. Investigators reported favorable metabolic changes in certain outcomes. However, the formulation provided two different dietary fibers, so the observed results cannot be attributed to glucomannan independently. This is a combination-formulation exposure rather than evidence for a 1.5 g/day isolated-glucomannan effect. (Research)
Result: Preliminary signal
Evidence strength: Limited
Notes / limitations: The study did not isolate the effects of the two fibers.
2.52 g/day:
A four-week randomized study compared glucomannan with placebo in 80 children with functional constipation. Researchers examined constipation-related outcomes, including treatment success and gastrointestinal symptoms. Glucomannan did not produce a statistically significant improvement in overall treatment success, and abdominal discomfort was reported during parts of the intervention. The study demonstrates that increasing exposure to a water-binding fiber does not guarantee broader improvement in constipation. Its findings apply to a pediatric clinical population rather than healthy adults. (Research)
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: Pediatric findings cannot automatically be extrapolated to other ages or constipation subtypes.
3 g/day — weight-management and lipid outcomes:
A twelve-week randomized trial examined glucomannan added to a carbohydrate-restricted dietary intervention in 30 men with overweight or obesity. The researchers measured weight changes and cardiometabolic markers. Both intervention groups lost weight, while the addition of glucomannan did not provide a clear overall weight-loss advantage. Selected LDL cholesterol findings were more favorable, illustrating that the same exposure can affect lipid markers without producing additional weight reduction. The dietary background is important because the experimental comparison was not glucomannan versus an otherwise unchanged habitual diet. (Research)
Result: Mixed findings
Evidence strength: Limited
Notes / limitations: The concurrent carbohydrate-restricted diet limits attribution of overall changes to glucomannan.
3 g/day — pediatric Obesity and Weight Regulation:
A randomized placebo-controlled investigation evaluated 3 g/day of glucomannan in 96 children and adolescents with overweight or obesity. The supplementation phase lasted twelve weeks, with additional follow-up. The primary body-weight-related outcome, BMI-for-age, did not improve significantly compared with placebo. Researchers observed changes in some secondary blood lipid measurements, but those findings did not alter the neutral conclusion for weight management. The study adds a pediatric perspective to the predominantly short-term body-weight literature. (Research)
Result: No clear effect on body-weight outcome
Evidence strength: Moderate
Notes / limitations: Secondary lipid findings should not be confused with the primary weight-related outcome.
3.9 g/day:
A placebo-controlled crossover study administered 3.9 g/day to 63 healthy men in two four-week intervention periods. The investigators measured total cholesterol, LDL cholesterol, and triglycerides. Compared with placebo, the glucomannan intervention was associated with reported reductions of approximately 10%, 7.2%, and 23%, respectively. The study is particularly informative because it examined lipid changes in participants without the metabolic conditions represented in some later research. Nevertheless, the intervention assessed lipid biomarkers rather than cardiovascular events. (Research)
Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The study was short and did not evaluate cardiovascular disease outcomes.
3.99 g/day:
A randomized trial evaluated glucomannan at 1.33 g three times daily, totaling approximately 3.99 g/day, in 53 adults with overweight or moderate obesity. The intervention lasted eight weeks. Researchers measured body weight, body composition, and subjective appetite-related outcomes. Glucomannan did not result in significantly greater weight loss than placebo, nor did it establish consistent improvements in the other principal outcomes. This neutral finding is especially relevant when interpreting the ingredient’s experimental weight-management literature. (Research)
Result: No clear effect
Evidence strength: Moderate
Notes / limitations: The eight-week study cannot characterize effects over substantially longer periods.
Upper and mixed-exposure research
Up to 15.1 g/day — reported exposure range in safety summaries:
NIH ODS summarizes glucomannan research involving a range of oral exposures, including amounts substantially higher than those used in common weight-management trials. These exposures were studied over limited durations and in different preparations. Gastrointestinal symptoms, including loose stools, flatulence, and abdominal discomfort, have been documented. The presence of higher experimental exposure does not establish an optimal or universally safe intake range, especially given the ingredient’s water-swelling properties. The upper range is therefore useful as safety-research context rather than evidence of additional efficacy. (NIH ODS)
Result: Inconclusive for clinical efficacy at the upper exposure range
Evidence strength: Limited
Notes / limitations: This range comes from a research synthesis rather than one directly comparable dose-escalation trial.
Key Takeaways from Human Research
– Blood lipids show the most reproducible response. Multiple randomized trials and systematic reviews report lower LDL and total cholesterol following glucomannan exposure, although effect sizes differ across studies. (Review)
– Weight loss remains unconvincing as an isolated effect. Randomized trials have frequently found no statistically significant body-weight advantage over placebo, and a meta-analysis did not identify a significant pooled benefit. (Research) (Review)
– Constipation outcomes are mixed. Some studies report more frequent bowel movements, but overall treatment success has not improved consistently in pediatric randomized research. (Review)
– Glucose-related findings are preliminary. Selected studies report favorable metabolic markers, but small populations, food-based formulations, and differing analyses limit confidence in durable glycemic effects. (Research) (Review)
– Food structure and viscosity matter. Acute feeding research demonstrates that differences in gel consistency can influence subjective fullness without necessarily producing a substantial reduction in subsequent eating. (Research)
– Safety depends partly on physical behavior. Glucomannan’s capacity to absorb water creates clinically relevant swallowing and obstruction concerns separate from its ordinary gastrointestinal side effects. (FDA)
Origin & Natural Occurrence
Glucomannan is naturally present in the konjac plant, Amorphophallus konjac, particularly within its underground storage organ. The polysaccharide consists primarily of mannose and glucose joined into a long carbohydrate chain. Its ability to interact strongly with water explains much of its use as a dietary fiber and food-texture ingredient. (NIH ODS) (EFSA)
The human body does not synthesize konjac glucomannan as an endogenous nutrient. Instead, the fiber is consumed through konjac-derived foods or preparations containing extracted and processed glucomannan. Commercial ingredient manufacturing generally involves isolating and refining the polysaccharide from plant material, after which it may be incorporated into powders, capsules, gels, or other foods. (EFSA)
The terms konjac gum and konjac glucomannan are sometimes used closely in food and ingredient contexts, but regulatory descriptions can distinguish preparations according to their composition and processing characteristics. These distinctions matter when relating research on a specific preparation to other formulations. (EFSA)
How It Behaves in the Body
Glucomannan acts primarily through its physical behavior in the digestive tract. When exposed to water, the fiber hydrates and can create a viscous mixture that changes how food moves and mixes within the gastrointestinal environment. Because it is not digested like ordinary starch or sugar, much of its immediate activity takes place locally in the gut rather than through absorption of the intact polymer into the bloodstream. (NIH ODS)
One investigated consequence is the relationship between fiber viscosity and lipid metabolism. Highly viscous soluble fibers can change the intestinal environment in ways that influence bile acids and cholesterol handling. Human glucomannan research has measured both reductions in circulating LDL cholesterol and changes in fecal sterol or bile acid excretion, providing complementary evidence of gastrointestinal involvement in lipid regulation. (Research)
A second area involves the physical movement and absorption of nutrients. Glucomannan-containing foods have been studied for changes in glucose-related measurements, including fructosamine and fasting glucose. These findings are consistent with the broader idea that viscous fibers can influence nutrient handling, although the trials do not establish one universal response across every meal composition or metabolic population. (Research) (Review)
A third area concerns fullness and appetite. By altering the consistency and volume of gastrointestinal contents, glucomannan-containing formulations may affect sensations of fullness. However, controlled feeding research shows that increased subjective fullness does not always lead to a meaningful reduction in subsequent energy intake, helping explain why appetite mechanisms and long-term weight outcomes do not necessarily align. (Research) (Review)
Within the large intestine, glucomannan may participate in microbial fermentation and other fiber-related interactions, but the magnitude and consistency of those processes depend on the research setting and formulation. A combination study involving glucomannan and other ingredients examined metabolic outcomes, but it does not independently establish a glucomannan-specific microbiome-mediated clinical effect. (Research)
The best-established human observations concern changes in digestive physical properties and selected lipid measurements. Specific molecular explanations for longer-term body-weight regulation, glycemic improvement, or gut-microbiota-mediated effects remain less definitively established by the clinical studies reviewed here. (Review) (Review)
Absorption & Delivery Formats
Oral immediate-release
Oral administration is the principal route represented in human glucomannan research. Studies have used capsules, powders, and fiber incorporated into foods, with outcomes measured through gastrointestinal responses, changes in circulating metabolic markers, and body-weight assessments. The ingredient’s physical hydration behavior is particularly important to interpreting these formulations. (Research) (NIH ODS)
Food-based and gelled formulations
Food-based research includes biscuits, enriched yogurt, gel noodles, and meals designed to vary in viscosity. These investigations have examined appetite, glucose-related responses, or lipid measures, but changing a food formulation can also change energy density, other nutrients, and the physical characteristics of the meal. Therefore, results from glucomannan-containing foods are not necessarily equivalent to those from isolated glucomannan preparations. (Research) (Research)
Oral extended-release
The collected human evidence does not provide a well-characterized comparison of extended-release glucomannan products with conventional oral formulations. Because glucomannan’s relevant behavior depends substantially on hydration and gel formation, ordinary terminology used for extended-release medicines cannot automatically be transferred to glucomannan fiber preparations.
Sublingual
The reviewed research does not establish sublingual absorption or clinically meaningful effects of glucomannan delivered beneath the tongue. The large dietary polymer and its gastrointestinal study context make oral ingestion substantially better characterized than sublingual administration.
Transdermal
No controlled human transdermal glucomannan exposure study was identified in the selected clinical evidence. The results from oral fiber investigations cannot be used to infer systemic delivery or metabolic benefits through the skin.
Injectable / IV
The selected human clinical studies do not support an injectable or intravenous glucomannan administration framework for the nutritional and metabolic outcomes discussed in this article. Those routes should not be inferred from the presence of glucomannan as a material used in unrelated experimental technologies.
Quick Facts at a Glance
Onset (reported)
Glucomannan’s initial physical behavior involves hydration and development of viscosity within the gastrointestinal environment. Acute feeding studies have assessed fullness and subsequent food consumption during the hours following a test meal, whereas clinical trials examining cholesterol, body weight, or bowel function have generally followed participants for several weeks. A single clinically meaningful onset time has not been established across these different outcomes. (Research) (Research)
Time to peak (Tmax)
A conventional plasma time-to-peak value is not established for intact glucomannan in the cited human evidence. Unlike a readily absorbed small molecule, glucomannan is primarily studied as a nondigestible, water-binding dietary polymer. Research therefore focuses on gastrointestinal and metabolic responses rather than the concentration of intact glucomannan circulating in blood. (NIH ODS)
Half-life (t½)
The cited human trials do not define a conventional systemic elimination half-life for intact glucomannan. Its effects are assessed in relation to food intake, gastrointestinal transit, and repeated exposure rather than drug-like plasma elimination. A precise half-life number would therefore be misleading without a specific measurement and experimental definition. (Research) (NIH ODS)
Typical duration
Acute feeding investigations have examined responses over hours, while constipation and lipid trials have commonly lasted approximately four to twelve weeks. Weight-management research has similarly relied heavily on short-term follow-up, limiting confidence in sustained effects over longer periods. Study duration represents the observation window rather than the established duration of an effect after exposure stops. (Research) (Review)
Absorption routes studied
The research reviewed here concentrates on oral exposure, including capsules and incorporation into food. Biological responses are measured indirectly through digestion, bowel function, circulating lipids, and glycemic markers rather than through systemic absorption of the intact fiber. Evidence for alternative delivery routes is insufficient within this clinical literature. (Research) (Research)
Formulation differences
Glucomannan has been studied as concentrated fiber and within foods that differ considerably in texture and viscosity. An acute crossover trial found that more viscous formulations increased reported fullness, although the difference in subsequent food intake was small. This demonstrates that the physical structure of the formulation can influence measured responses without guaranteeing meaningful changes in weight. (Research)
Variability drivers
Potential sources of variation include glucomannan amount, hydration, food structure, participant dietary background, baseline metabolic status, and study outcome definitions. Trials using enriched foods or multi-ingredient combinations introduce additional uncertainty because other ingredients can contribute to the measured response. These considerations help explain why results from different preparations should not automatically be regarded as equivalent. (Research) (Research)
Tolerance / adaptation
The collected studies do not establish a defined tolerance syndrome or a reproducible reduction in glucomannan response after repeated exposure. Most trials were designed to evaluate outcomes such as cholesterol, weight, or bowel function rather than progressive physiological adaptation. Consequently, a standardized tolerance timeline cannot be drawn from this evidence. (Research)
Evidence strength snapshot
Evidence is moderate for improvements in total and LDL cholesterol measurements but limited or mixed for body weight, bowel-function outcomes, and longer-term glycemic control. Several evidence syntheses have identified heterogeneity in study methods and results. The most reproducible measured effects should therefore be distinguished from unproven changes in disease incidence or clinical complications. (Review) (Review) (Review)
Safety, Interactions & Regulation
Adverse effects
The adverse effects reported in human glucomannan research are mainly gastrointestinal, including abdominal discomfort, bloating, flatulence, and changes in stool consistency. Not every trial has identified significant differences in adverse events compared with placebo, but tolerability can vary by participant characteristics, formulation, and exposure. (NIH ODS) (Research)
A distinct safety concern arises from glucomannan’s ability to absorb substantial amounts of water and expand. U.S. regulatory documentation identifies esophageal obstruction and choking-related hazards associated with certain water-swelling gum preparations, particularly when swallowed without adequate fluid or by people with swallowing difficulties. This is a physical administration hazard rather than an indication of systemic toxicity. (FDA)
Interaction categories
Oral medications and nutrient absorption: Glucomannan’s capacity to increase gastrointestinal viscosity provides a plausible basis for concern about changes in the timing of absorption of concurrently ingested substances. However, the collected human trials do not establish a universal effect or a precise interaction interval for individual medications. Its physical gastrointestinal behavior is described in official ingredient assessments. (NIH ODS)
Glucose-regulating interventions: Controlled studies in people with type 2 diabetes have reported changes in glucose-related markers following glucomannan-containing interventions. Such findings establish a reason to consider concurrent glucose-lowering treatment when interpreting study results, but they do not quantify an interaction with any particular medication. (Research) (Review)
Other fermentable or viscous fibers: Combination studies have administered glucomannan alongside ingredients such as inulin and fructooligosaccharides. These trials can evaluate a combined formulation but cannot independently establish whether the physiological response came from glucomannan, the additional fiber, or their interaction. (Research) (Research)
Population cautions
People with swallowing difficulties or known narrowing of the gastrointestinal tract require particular consideration in safety interpretation because water-swelling fiber preparations can create a mechanical obstruction hazard. The degree of risk cannot be assumed identical across powders, capsules, gels, and prepared foods. (FDA)
Pediatric constipation trials have included children with existing gastrointestinal symptoms, with some studies reporting abdominal discomfort and no significant overall benefit. Results obtained from otherwise healthy adult weight-management participants should not automatically be generalized to such clinical populations. (Research) (Research)
The collected trials provide insufficient evidence to characterize pregnancy-specific outcomes, rare adverse events, or lifelong exposure to concentrated glucomannan formulations.
U.S. regulatory status
In the United States, glucomannan appears in the dietary supplement and food-ingredient context. NIH ODS discusses glucomannan in its official assessment of ingredients investigated for weight management and concludes that evidence for meaningful weight-loss effects is limited. (NIH ODS)
The FDA’s regulatory material concerning water-swelling gums addresses the potential for choking and esophageal obstruction in relevant oral preparations. This safety documentation should not be interpreted as evidence that glucomannan is approved to treat constipation, obesity, high cholesterol, or diabetes. (FDA)
EU regulatory status
The European Union permits specified health claims for glucomannan under defined conditions of use. These include a claim concerning maintenance of normal blood cholesterol concentrations and a separate claim concerning weight loss in the context of an energy-restricted diet. Authorization is conditional and does not mean that every glucomannan-containing product, exposure, or study population has demonstrated the claimed effect. (EU Regulation)
EFSA has also evaluated the safety of konjac gum and konjac glucomannan in the context of food additive use. Such assessments address specified ingredient uses and safety considerations and should be kept distinct from the evaluation of clinical effectiveness. (EFSA)
Evidence Overview
Glucomannan has been investigated through randomized controlled trials, crossover feeding experiments, pediatric studies, and systematic reviews. The strongest and most consistent human evidence concerns reductions in total and LDL cholesterol, whereas findings for Obesity and Weight Regulation, Digestive and Gastrointestinal Health, and Diabetes and Glycemic Control are less consistent. Evidence confidence is constrained by small study populations, relatively short interventions, diverse formulations, and the frequent use of physiological markers rather than long-term clinical endpoints. (Review) (Review) (Review)
For Cardiovascular Health, several randomized trials have reported reductions in circulating LDL cholesterol after glucomannan supplementation. A systematic review and meta-analysis of 12 trials involving 370 participants found favorable effects on LDL and non-HDL cholesterol, supporting a reproducible lipid-related physiological response. However, results for apolipoprotein B were less clear, and the pooled trials did not establish reductions in cardiovascular events. (Review)
Later evidence syntheses broadly support the possibility of modest cholesterol improvements while emphasizing heterogeneity between trials. Differences in baseline lipid levels, dietary background, intervention duration, and glucomannan exposure may partly explain variation in effect estimates. The clinical importance of modest biomarker changes remains a separate question from whether the changes are statistically significant. (Review) (Review)
For Obesity and Weight Regulation, the evidence is less favorable than the ingredient’s proposed appetite mechanism might imply. Glucomannan can increase the viscosity of food and influence fullness, but controlled trials have frequently found no significant difference in body-weight reduction compared with placebo. A meta-analysis of eight randomized trials did not identify a statistically significant overall weight-loss effect. This distinction illustrates why measurable short-term satiety responses cannot automatically be extrapolated to sustained weight change. (Research) (Review)
Research on Digestive and Gastrointestinal Health also illustrates the importance of outcome selection. Some pediatric trials have reported improvements in bowel-movement frequency, yet other trials have not found a significant difference in overall constipation-treatment success. Meta-analytic evidence similarly indicates that individual stool-related endpoints can improve without establishing a consistent broader treatment effect. (Research) (Review)
For Diabetes and Glycemic Control, earlier small crossover trials reported changes in fasting glucose and fructosamine when glucomannan was administered in supplements or fortified foods. Later pooled research has yielded favorable findings for selected outcomes, although some results are sensitive to analytical assumptions and study selection. This limits confidence in generalizing short-term biochemical changes to long-term complications of diabetes. (Research) (Review)
An additional difficulty is the diversity of interventions labeled as glucomannan research. Some studies use relatively isolated glucomannan, whereas others employ enriched foods containing inulin, fructooligosaccharides, chromium, or additional active ingredients. Outcomes from combination formulations cannot establish the independent effectiveness of glucomannan without an appropriate comparison that separates those contributions. (Research) (Research)
Stronger future evidence would come from larger independently replicated trials using standardized preparations, clearly described hydration and administration methods, longer observation periods, and consistent clinically relevant endpoints. For lipid research, this would include clearer links between changes in circulating markers and subsequent cardiovascular outcomes. For weight, glycemic, and gastrointestinal research, studies would benefit from distinguishing short-term physiological effects from sustained clinical improvements. These priorities reflect the limitations identified across the existing clinical evidence. (Review) (Review)
Evidence Confidence Classification
Moderate for lipid-marker outcomes, but Limited / Mixed overall for broader clinical effects, is the evidence classification for glucomannan, based on repeated randomized findings for LDL cholesterol alongside less consistent results for weight, constipation, and glycemic outcomes. (Review) (Review)
Cardiovascular Health research provides the most reproducible intermediate-outcome signal, although favorable lipid changes have not established reductions in cardiovascular events. Obesity and Weight Regulation research is less convincing, with neutral randomized trials and pooled results. (Review) (Review)
Digestive and Gastrointestinal Health and Diabetes and Glycemic Control remain limited or mixed because the studies differ in outcome definitions, patient populations, and administered formulations. Mechanistic explanations involving viscosity and digestive physiology are plausible and informative, but they are not substitutes for reliable demonstrations of longer-term clinical benefit. (Review) (Review)
Similar Ingredients & Comparators
Similar supplement-style ingredients
- Psyllium husk
- Beta-glucan
- Guar gum
- Pectin
- Methylcellulose
- Inulin
- Fructooligosaccharides
- Resistant starch
- Partially hydrolyzed guar gum
- Acacia fiber
These ingredients share one or more relevant properties, such as dietary fiber content, viscosity, fermentability, or investigation for digestive and metabolic outcomes. They should not be treated as interchangeable without ingredient-specific comparative evidence.
Medical / pharmaceutical comparator categories
- Lipid-lowering medication classes
- Prescription weight-management therapies
- Bulk-forming laxatives
- Osmotic laxatives
- Other constipation-management medications
- Glucose-lowering medication classes
These categories are presented for research orientation only, not as substitutes or equivalent interventions.
Combination Context
Glucomannan + Inulin:
A randomized study evaluated yogurt containing 1.5 g/day of glucomannan and 1.5 g/day of inulin in adults with type 2 diabetes. The intervention reported favorable changes in selected metabolic outcomes, but the study design did not determine which fiber contributed to those results. (Research)
Glucomannan + Fructooligosaccharides:
Human crossover research has examined a multi-ingredient complex containing glucomannan and fructooligosaccharides, alongside chromium, for post-meal glucose, insulin, and satiety responses. The acute experimental design and simultaneous presence of multiple ingredients prevent attribution of the results to glucomannan alone. (Research)
Glucomannan + Inulin + Cinnamon + D-Chiro-Inositol:
A sixteen-week randomized investigation studied a multi-ingredient formulation in adults with metabolic syndrome. Selected metabolic measurements improved, but the combined intervention does not establish the independent contribution of glucomannan. (Research)
FAQ
What is glucomannan?
Glucomannan is a soluble, highly viscous dietary fiber obtained primarily from the konjac plant, Amorphophallus konjac. It consists mainly of glucose and mannose units linked into a large carbohydrate polymer. Its ability to hydrate and thicken gastrointestinal contents is central to the physiological effects investigated in humans. (NIH ODS) (EFSA)
What does human research study glucomannan for?
Human research principally examines Cardiovascular Health, Obesity and Weight Regulation, Digestive and Gastrointestinal Health, and Diabetes and Glycemic Control. Studies have measured LDL cholesterol, body weight, bowel-movement outcomes, and glucose-related markers. Evidence is strongest for improvements in selected blood lipid measurements and less consistent for other outcomes. (Review) (Review)
What are glucomannan’s best-supported effects?
The best-supported human finding is a reduction in LDL and total cholesterol in some randomized supplementation trials. Meta-analyses have found favorable pooled lipid changes, although the effect size varies between populations and interventions. These outcomes describe cardiovascular risk markers and do not demonstrate fewer heart attacks or strokes. (Review) (Review)
Does glucomannan help with weight loss?
Glucomannan has been investigated for weight management because its viscosity may influence feelings of fullness. However, an eight-week randomized trial did not find significantly greater weight loss than placebo. A meta-analysis of randomized trials similarly found no statistically significant overall weight-loss effect, making the clinical findings limited or mixed. (Research) (Review)
Does glucomannan reduce LDL cholesterol?
Multiple randomized studies have reported lower LDL cholesterol after glucomannan exposure. A 2017 meta-analysis of twelve trials involving 370 participants found reductions in LDL and non-HDL cholesterol. The evidence concerns blood lipid measurements rather than the direct prevention of cardiovascular events, and the magnitude of change is not identical across studies. (Review)
What does research show about constipation?
Some human trials have investigated whether glucomannan improves stool frequency and related constipation symptoms. A pediatric meta-analysis found an increase in bowel-movement frequency but did not establish significantly better overall treatment success. A separate randomized pediatric trial also reported no meaningful improvement in overall success compared with placebo, supporting a mixed evidence classification. (Review) (Research)
Does glucomannan affect blood glucose?
Small controlled trials have reported favorable changes in selected glucose-related measurements, including fasting glucose or fructosamine. Systematic reviews have also examined these outcomes, but conclusions vary with the included populations, formulations, and analytical methods. Consequently, the evidence does not establish a consistent long-term effect on diabetes-related clinical complications. (Research) (Review)
How quickly does glucomannan act?
Glucomannan can hydrate and change the viscosity of gastrointestinal contents after ingestion. Acute feeding studies have evaluated subjective fullness and food intake during the hours following consumption, while trials of cholesterol and bowel function have generally measured outcomes over weeks. There is no single established onset time applicable to every researched physiological effect. (Research) (Research)
What affects absorption and variability?
Glucomannan’s studied effects depend largely on its physical behavior in the digestive tract rather than systemic absorption of the intact polymer. Formulation, hydration, food texture, and viscosity can influence measured responses, including fullness. Differences in background diet and concurrent ingredients also make comparisons between trials less straightforward. (Research) (Research)
Is tolerance to glucomannan reported?
The collected clinical evidence does not establish a recognized tolerance syndrome associated with repeated glucomannan exposure. Most randomized trials have concentrated on cholesterol, weight, bowel function, or metabolic markers instead of systematically measuring declining responsiveness over time. The absence of such measurements means that a precise tolerance or adaptation pattern cannot be established. (Research) (Review)
Why do glucomannan studies disagree?
Trials differ in glucomannan exposure, formulation, population, dietary background, duration, and the outcomes measured. A change in fullness or LDL cholesterol is not the same endpoint as a sustained reduction in body weight or cardiovascular events. Studies that combine glucomannan with other ingredients create additional uncertainty because they cannot isolate the fiber’s independent contribution. (Review) (Research)
What ingredients has glucomannan been combined with in human research?
Published human trials have examined glucomannan with inulin, fructooligosaccharides, chromium, cinnamon, and D-chiro-inositol. These formulations have generally been investigated for selected glucose, insulin, satiety, or other metabolic markers. The results describe the tested combinations and do not prove that glucomannan independently caused the observed outcomes. (Research) (Research)
What foods naturally contain glucomannan?
The principal natural source is konjac, a plant whose underground storage organ contains glucomannan-rich material. Konjac-derived ingredients are used in certain foods, including gelled and noodle-like products. The fiber content and physical characteristics of these foods can differ considerably from concentrated glucomannan preparations studied in clinical trials. (EFSA) (Research)
Is glucomannan safe?
Randomized trials have generally reported gastrointestinal tolerability outcomes, including abdominal discomfort and changes in bowel habits. An important additional concern is that concentrated water-swelling preparations can create a choking or esophageal obstruction risk under certain conditions. U.S. regulatory material specifically addresses this mechanical hazard, which should not be overlooked when evaluating safety. (Research) (FDA)
Does glucomannan interact with medications?
Glucomannan’s gastrointestinal viscosity creates a plausible concern about changes in the absorption timing of concurrently ingested substances, but the studies reviewed here do not establish a precise interaction magnitude for individual medications. Trials involving participants with type 2 diabetes have also reported changes in glucose-related measurements. These observations identify research-relevant interaction categories rather than documenting a uniform interaction with every oral medication. (NIH ODS) (Research)
How is glucomannan regulated?
In the United States, glucomannan is discussed by NIH ODS as an ingredient used in dietary supplements, including products investigated for weight management. FDA documentation also addresses mechanical hazards associated with water-swelling gums in relevant oral preparations. In the European Union, specified glucomannan health claims are authorized subject to defined conditions, while EFSA has assessed the safety of konjac gum and glucomannan as food additives. (NIH ODS) (FDA) (EU Regulation) (EFSA)
Resources
1. Dietary Supplements for Weight Loss — Health Professional Fact Sheet — NIH Office of Dietary Supplements — https://ods.od.nih.gov/factsheets/WeightLoss-HealthProfessional/
2. Glucomannan and LDL Cholesterol: Systematic Review and Meta-Analysis — PubMed-indexed systematic review, 2017 — https://pubmed.ncbi.nlm.nih.gov/28356275/
3. Glucomannan and Weight Loss: Systematic Review and Meta-Analysis — PubMed-indexed systematic review, 2014 — https://pubmed.ncbi.nlm.nih.gov/24533610/
4. Glucomannan and Multiple Cardiometabolic Outcomes: Meta-Analysis — PubMed-indexed systematic review, 2008 — https://pubmed.ncbi.nlm.nih.gov/18842808/
5. Glucomannan and Blood Lipids: Randomized Crossover Trial — Arvill and Bodin, 1995 — https://pubmed.ncbi.nlm.nih.gov/7872224/
6. Glucomannan in Adults With Overweight or Obesity — Keithley et al., 2013 — https://pubmed.ncbi.nlm.nih.gov/24490058/
7. Glucomannan for Childhood Constipation: Randomized Trial — Chmielewska et al., 2011 — https://pubmed.ncbi.nlm.nih.gov/21320737/
8. Glucomannan for Childhood Constipation: Systematic Review — PubMed-indexed meta-analysis, 2017 — https://pubmed.ncbi.nlm.nih.gov/28429913/
9. Glucomannan and Type 2 Diabetes: Randomized Crossover Research — Vuksan et al., 1999 — https://pubmed.ncbi.nlm.nih.gov/10372241/
10. FDA Administrative Order — OTC Laxative Drug Products — U.S. Food and Drug Administration — https://www.accessdata.fda.gov/drugsatfda_docs/omuf/Order/Final%20Administrative%20Order%20OTC000032_M007-Laxative%20Drug%20Products%20for%20OTC%20Human%20Use.pdf
11. Re-evaluation of Konjac Gum and Konjac Glucomannan — European Food Safety Authority — https://www.efsa.europa.eu/en/efsajournal/pub/4864
12. EU Authorized Health Claims Regulation — European Commission, Regulation (EU) No 432/2012 — https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX%3A32012R0432